ArticleFrontiers in psychiatry2026
Peripheral immune and kynurenine profiles are associated with cognitive change during early treatment of first-episode schizophrenia.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To delineate the longitudinal relationships among peripheral inflammation, kynurenine pathway (KP) dysregulation, immune-cell redistribution, and cognitive performance in antipsychotic-naïve first-episode schizophrenia (FES). Methods: Antipsychotic-naïve FES patients (n = 136) and healthy controls (HC; n = 136) were enrolled. FES received aripiprazole monotherapy through week 6, followed by naturalistic treatment through month 6. Cognition was assessed with the MATRICS Consensus Cognitive Battery (MCCB). Plasma KP metabolites were quantified by LC-MS/MS, inflammatory markers by high-sensitivity ELISA, and immune-cell subsets by flow cytometry. Results: FES showed marked baseline cognitive impairment with stepwise improvement by week 6 and month 6. At baseline, FES demonstrated a KP shift toward a relatively more neurotoxic profile (lower TRP and KYNA, higher KYN/TRP, 3-HK, and QA, with elevated QA/KYNA and reduced KYNA/3-HK), heightened inflammation (higher hs-CRP and pro-inflammatory cytokines with lower IL-10), and monocyte-skewed redistribution (higher CD14 Conclusions: Antipsychotic-naïve FES shows marked cognitive impairment with heightened inflammation, monocyte shifts, and KP dysregulation. Over follow-up, cognitive performance was more closely aligned with stable between-person immuno-KP differences, while cognitive improvement most consistently tracked KP remodeling rather than broad inflammatory or cellular change.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.